Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 16/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1380483 | 0.91 | MAOA (0.77) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13089915 | 0.89 | MAOA (0.65) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1378948 | 0.86 | CALML3 (0.65) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13760401 | 0.85 | MAOA (0.62) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10261492 | 0.83 | MAOA (0.81) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10197417 | 0.83 | MAOA (0.81) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5756211 | 0.82 | MAOA (0.74) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16789959 | 0.82 | MAOA (0.74) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10197415 | 0.82 | MAOA (0.74) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10267519 | 0.82 | MAOA (0.74) | MAOACYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816379-B2 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2010-10-19 | — | — | US | disclosed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | ALPI, SI, TST | MAOA 4398/4885CYP3A4 68/4885CYP2D6 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.